Questionnaire

1. Upon oral glucose challenge, insulin secretion is due to the combined effect of hyperglycaemia and incretin hormones.

2. IV glucose challenge gives rise to increased secretion of:

3. GIP increases plasma glucagon in states of:

4. High levels of GIPR expression have been reported in:

5. A notable effect of GIP on adipose tissue is increased:

6. GIP affects tissue lipid metabolism under fasting conditions:

7. Plasma GLP-1 and GIP secretion are maintained during four-hour oral glucose tolerance testing in people who:

8. β-cell function and responsiveness to GIP may be restored after improved glycaemic control:

9. A next-generation incretin therapy, tirzepatide, is:

10. Plasma concentrations of tirzepatide are affected by:

11. Combined GIPR/GLP-1R agonism has been demonstrated to have indirect effects on the:

12. The receptor-binding affinity of tirzepatide is similar to that of native:

13. In the SURPASS programme, tirzepatide reduced HbA1c from baseline to the primary endpoint to a greater extent than:

14. In terms of weight reduction, findings from the SURPASS programme demonstrated that all tirzepatide doses were superior to:

15. An increased risk for clinically significant or severe hypoglycaemia in tirzepatide-treated participants in the SURPASS-2 study was observed with concurrent use of: